NUDT17: A Potential Drug Target and Biomarker (G200035)

Target Name: NUDT17

NCBI ID: G200035

NUDT17

NUDT17: A Potential Drug Target and Biomarker

NUDT17, also known as nudix motif 17, is a protein that is expressed in various tissues and cell types in the body. It is a member of the NUDT family, which is known for its role in regulating DNA repair and has been implicated in a number of cellular processes, including cell division, apoptosis, and inflammation. NUDT17 has also been shown to play a role in the development and progression of a variety of diseases, including cancer. As a result, NUDT17 has potential as a drug target and biomarker.

The discovery and characterization of NUDT17

NUDT17 was first identified in the 1990s by researchers using DNA-based screening approaches. Since then, several studies have confirmed its presence in a variety of tissues and cell types, including liver, pancreas, and brain. NUDT17 has also been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

The functions of NUDT17

NUDT17 is involved in a number of cellular processes that are important for its overall function. One of its primary functions is the regulation of DNA repair. DNA repair is a critical process that helps cells maintain the integrity of their genetic material and prevent mutations that can cause diseases. NUDT17 is involved in this process by ensuring that damaged DNA is correctly repaired and that repair templates are available for the cell to use.

In addition to its role in DNA repair, NUDT17 is also involved in the regulation of cell division and apoptosis. It is known to play a role in the G1 phase of cell division and is thought to help ensure that cells have enough copies of their genetic material before they enter the S phase. NUDT17 is also involved in the regulation of apoptosis, a process that helps cells eliminate damaged or dysfunctional components.

The potential implications of NUDT17 as a drug target

The potential implications of NUDT17 as a drug target are significant. NUDT17 has been shown to play a role in the development and progression of a variety of diseases, including cancer. By targeting NUDT17, researchers may be able to develop new treatments for these diseases. Additionally, NUDT17 may also be a useful biomarker for tracking the effectiveness of existing treatments.

The development of NUDT17 as a drug target is currently being investigated in a number of different settings. For example, researchers are working to develop small molecules that can inhibit the activity of NUDT17 and use this approach to develop new treatments for cancer. Additionally, researchers are also exploring the use of NUDT17 as a biomarker to monitor the effectiveness of cancer treatments.

The potential applications of NUDT17 as a drug target and biomarker are vast and continue to be explored by researchers. As more studies are conducted, NUDT17 is likely to play an increasingly important role in the development of new treatments for a variety of diseases.

Protein Name: Nudix Hydrolase 17

Functions: Probably mediates the hydrolysis of some nucleoside diphosphate derivatives

The "NUDT17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDT17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets